Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL-225 vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/m L.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2 and to a lesser extent CYP2E1, CYP3A4; exhibits nonlinear pharmacokinetics at high concentrations.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40% bound to albumin (primarily); binding is concentration-independent.
55–65% bound to plasma proteins, primarily albumin.
0.3–0.7 L/kg; distributes freely into tissues and breast milk; Vd reflects moderate tissue penetration and rapid equilibration.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 100% (complete absorption); bioavailability not significantly affected by food. Rectal: ~80% (variable due to absorption site).
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific GFR-based adjustment required; monitor serum theophylline levels as renal impairment may affect clearance.
No dose adjustment required for renal impairment.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 50-75%; Child-Pugh C: reduce dose by 75-90% or consider alternative. Frequent serum level monitoring is mandatory.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Initial: 5 mg/kg orally every 6 hours; titrate based on serum levels. Usual maintenance: 10-20 mg/kg/day divided every 6 hours. Not recommended under 1 year without specialist advice.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at lower dose (e.g., 112.5 mg every 6 hours) due to decreased clearance; titrate slowly with close serum level monitoring. Target lower end of therapeutic range (8-12 mcg/m L) if tolerated.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Narrow therapeutic index; serum levels must be monitored (target 5-15 mcg/m L),Risk of seizure and cardiac arrhythmias at toxic levels,Increased seizure risk in patients with preexisting seizure disorders,Use with caution in liver impairment, congestive heart failure, and elderly,May cause tachycardia, palpitations, and exacerbation of arrhythmias
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or other xanthines (e.g., caffeine, theobromine),Pre-existing cardiac arrhythmias, particularly tachyarrhythmias,Active seizure disorder,Severe hepatic impairment
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid excessive caffeine from coffee, tea, cola, and chocolate which can increase side effects. High-protein, low-carbohydrate diets may increase theophylline clearance. Charcoal-broiled foods and cruciferous vegetables (e.g., broccoli, cabbage) may induce metabolism and lower levels.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Theophylline crosses the placenta. First trimester: No clear association with major malformations in human studies, but limited data. Second/third trimester: Risk of fetal tachycardia, jitteriness, and irritability at high maternal serum levels (toxicity). May cause transient neonatal withdrawal symptoms (apnea, vomiting) if used near term.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk; M/P ratio approximately 0.7. Infant serum levels can reach therapeutic levels, especially with maternal doses >10 mg/kg/day. Use with caution; monitor infant for signs of irritability or insomnia. AAP considers compatible with breastfeeding but observe infant.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Clearance of theophylline decreases in pregnancy, especially in third trimester, leading to prolonged half-life. Dose reduction may be required to avoid toxicity; monitor serum levels closely. Typically, total daily dose may need reduction by 20-30% in late pregnancy. Postpartum, clearance normalizes quickly, necessitating dose increase.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Theophylline has a narrow therapeutic index; target serum concentration is 5-15 mcg/m L. Monitor levels due to variable clearance. CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., rifampin, smoking) significantly alter levels. Use with caution in hepatic impairment, heart failure, and elderly. Slow IV infusion over 20-30 minutes for loading dose to avoid hypotension and arrhythmias. Caffeine and theobromine (chocolate) can increase toxicity risk.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take the medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and limit caffeine intake (coffee, tea, cola, chocolate) as they can affect drug levels.,Report symptoms of toxicity immediately: nausea, vomiting, diarrhea, restlessness, insomnia, rapid heartbeat, or seizures.,Do not crush or chew sustained-release tablets; swallow whole.,Keep all appointments for blood tests to monitor theophylline levels.,Inform your doctor of all medications you are taking, especially antibiotics, seizure medicines, and heart medications.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL-225 vs AEROLATE SR, answered by our medical review team.
THEOPHYL-225 is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL-225 and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL-225 is: 225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/m L.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL-225 and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL-225 is classified as Category C. Theophylline crosses the placenta. First trimester: No clear association with major malformations in human studies, but limited data. Second/third trimester: Risk of fetal tachycar. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.